IngredientsSperanskia Baill. (family Euphorbiaceae) is a small genus endemic to China, comprising three herbaceous perennial species: S. tuberculata (Bunge) Baill., S. cantonensis (Hance) Pax & K. Hoffm., and S. yunnanensis S. M. Hwang. The subject of this article, Speranskia tuberculata (Bunge) Baill., carries a binomial authorship in which the species epithet was first assigned by Alexander von Bunge and subsequently reclassified under the genus Speranskia by Henri Ernest Baillon.
The official pharmaceutical Latin designation used in Chinese herbal trade is Herba Speranskiae Tuberculatae. In traditional Chinese medicine (TCM), it is categorized as Pungent, Bitter, Warm, and Slightly Toxic; entering the Liver and Kidney meridians. The Chinese common name is 透骨草 (Tòu Gǔ Cǎo), a term that literally means "penetrate the bones herb," referencing its traditional reputation for deep-reaching effects on joints and bones. It is also known in English as Tuberculate Speranskia Herb.
Speranskia tuberculata is a perennial herb, 25–50 cm tall, few-branched, with stems bearing appressed pubescence. It prefers grassy slopes, grasslands, and thickets, usually in dry places. More specifically, this species is a drought-enduring endemic herb in northern China that is mainly distributed in the Chinese Loess Plateau (CLP) and adjacent areas, where it usually occurs in dry habitats such as xerothermophilous grasslands, sparse thickets, and forest edges. Its pollen is dispersed by wind, while seeds are dispersed by gravity. Its generation time is approximately one year.
The herb is widely distributed in Liaoning, Jilin, Henan, Hebei, Shanxi and other provinces in China. Phylogeographic research has shed light on the historical range of the species: ecological niche modeling suggests that the distribution of S. tuberculata has recently expanded northwards from the southern CLP, whereas it has experienced habitat loss in the south. Populations probably survived the last glacial maximum (LGM) in the southern CLP and experienced post-glacial expansion.
Although S. tuberculata is not listed in the IUCN Red List, it is exhibiting a general decreasing trend or even disappearing completely in many distributional areas. Novel polymorphic SSR markers have been developed to evaluate impacts of recent habitat fragmentation on the genetic diversity and structure of S. tuberculata, and to develop suitable conservation strategies for the species. The primary drivers of decline are identified as agricultural intensification and over-exploitation of natural population resources.
A significant source of confusion in the identification of this herb is the widespread use of the same Chinese name across botanically unrelated plants. At least 20 different plant species across 8 botanical families have been used under the name "Tou Gu Cao" in various regions of China. The two mainstream commercial varieties are Zhēn Zhū Tòu Gǔ Cǎo (Speranskia, dominant in northern China) and Fèng Xiān Tòu Gǔ Cǎo (Impatiens balsamina, dominant in eastern/southern China).
Other regional substitutes include: Tiě Xiàn Tòu Gǔ Cǎo (Clematis intricata, yellow-flowered clematis) used in Hebei and Beijing; Yáng Jiǎo Tòu Gǔ Cǎo (Incarvillea sinensis, horn-podded herb) used in northeast China; and various Vicia (wild pea) species used in northeast China. This persistent "same name, different plant" (同名异物) phenomenon remains one of the most significant quality control challenges for this herb in modern practice.
Commercially and clinically, Speranskia tuberculata is encountered in several forms. The whole dried plant (Herba Speranskiae Tuberculatae) is most commonly prepared as a decoction. Standard decoctions employ 9–15 g of dried herb. External application is also practiced, either as a pounded poultice applied directly to the skin or as a decoction prepared for washing affected areas.
Modern supplement preparations include water-based granular extracts, ethanolic tinctures, and aqueous extracts. Scientific studies have employed ethanol extraction (typically at 70% v/v ethanol) to produce standardized extracts for pharmacological evaluation. In one documented extraction protocol, 500 g of dried plant was pulverized and subjected to refluxing extraction with 8 L of 70% (v/v) ethanol at 75°C two times for 1 hour each time, after which the extract was concentrated under reduced pressure and dried at 50°C.
Laboratory investigations have also utilized solvent fractionation using petroleum ether, ethyl acetate, n-butanol, and aqueous fractions to isolate different chemical classes for specific bioassays.
Speranskia tuberculata (Bunge) Baill. has been used to prevent and treat many diseases in Chinese folk medicine. Its use is rooted in the theoretical framework of Traditional Chinese Medicine, in which it is classified within the category of herbs that dispel wind and eliminate dampness, relax tendons, activate blood circulation, and alleviate pain.
In practice, the whole plant has been used in Chinese folk medicine to prevent and treat arthralgia due to wind-dampness, beriberi caused by cold-wetness evil, and pyogenic infections, because of its good efficacy for expelling wind and dampness, relaxing muscles and joints, promoting blood circulation, and relieving pain.
The traditional indications as recorded in classical TCM materia medica sources encompass dermatophytosis due to cold-damp, sores and boils, rheumatoid arthritis, and contracture of muscles and bones. It is commonly used for arthritic and rheumatic conditions, sports injuries, and muscle stiffness, and is also applied externally as a herbal wash for skin conditions like eczema and boils.
Classical texts contain divergent opinions on its toxic potential. Some sources classify Tou Gu Cao as having slight toxicity (有小毒), particularly the Impatiens balsamina form, while the Ben Cao Yuan Shi records the Speranskia form as non-toxic (无毒).
The herb was traditionally incorporated into multi-herb decoctions alongside other wind-cold dispelling and blood-activating ingredients, reflecting the TCM approach of combining synergistic herbs to address complex presentations of musculoskeletal and dermatological disease. As one recent preclinical study noted, the herb's traditional use has remained clinically prevalent in China for centuries, yet although Speranskia tuberculata has been widely applied to prevent and treat various diseases in Chinese folk medicine, few investigations are reported on its chemical composition and pharmacologic effects, which obstructs further clinical uses.
Phytochemical investigation of Speranskia tuberculata has identified a diverse range of bioactive compounds. A landmark study published in the Journal of Natural Products (2000) by researchers from the Institute of Materia Medica, Chinese Academy of Medical Sciences, reported the isolation of a unique class of nitrogen-containing molecules: five novel polyoxygenated alkaloids, speranculatines A–C (3–5), speranskilatine A (6), and speranberculatine A (7), have been isolated from Speranskia tuberculata. Compounds 3–5, 6, and 7 have bipyridine, pyrrolylpyridine, and bipyrrole skeletons, respectively. This is the first time that these three alkaloid structural types have been reported. The structures of 3–7 were elucidated by spectroscopic methods, including 2D NMR techniques and X-ray crystallographic analysis.
A separate study confirmed the presence of additional non-alkaloid compounds: two compounds were isolated from the plant and identified as 18-hydroxy(-)-manool and β-sitosterol, both separated from this plant for the first time.
Taken together, the documented phytochemical profile includes:
Modern HPLC/MS profiling has revealed a far more complex chemical signature: approximately 300 compound peaks were identified in mass spectra of extracts of the herb Speranskia tuberculata. Among the 56 most intense peaks, 35 compounds, according to the literature, have anticancer, antitumour, antioxidant and anti-inflammatory effects. As one review noted more broadly: there is little to no research on this herb in regard to human disease or potential therapeutic applications, where only a small number of research articles have investigated chemical isolates describing inherent chemical components such as polyoxygenated alkaloids including speranculatines.
Evidence level: Preclinical (animal models) only. No human clinical trials identified.
The most systematically studied pharmacological properties of Speranskia tuberculata are its analgesic and anti-inflammatory effects. The primary study in this area was published in 2015 in the African Journal of Traditional, Complementary and Alternative Medicines by Zhou et al., conducted at Shanghai Seventh People's Hospital and the Key Laboratory of Standardization of Chinese Herbal Medicines.
Animals were orally administered the Speranskia tuberculata ethanol extract (STE) at doses of 125, 250, and 500 mg/kg. The analgesic effect was estimated in mice by the hot-plate test and the acetic acid-induced writhing test. The anti-inflammatory effect was assessed using a rat paw edema model elicited by fresh egg white and a mouse ear edema model caused by dimethylbenzene. The antipyretic effect was determined using the lipopolysaccharide (LPS)-induced rat fever model.
STE significantly and dose-dependently reduced the number of writhing responses in mice, prolonged reaction time of mice against heat stimulation, depressed egg white-induced paw edema in rats and the dimethylbenzene-caused ear edema in mice, but did not alleviate LPS-induced pyrexia in rats.
The investigators concluded that STE possesses evident analgesic and anti-inflammatory activities, but has no antipyretic effect. The dose-dependent nature of the findings across both pain models and both inflammatory models supports a genuine pharmacological signal, but all evidence is from animal models, which cannot be extrapolated directly to humans without further study.
A more recent study (2026), published in the Journal of Pain Research, incorporated Speranskia tuberculata as a constituent "monarch drug" in a compound TCM ointment evaluated in a rat model of mechanical allodynia. The prescription was structured to dispel wind-dampness, unblock collaterals, and relieve pain, with Cortex Erythrinae and Speranskia tuberculata as monarch drugs. Modern studies confirm the analgesic and anti-inflammatory properties of Speranskia tuberculata extract, and Cortex Erythrinae has been shown to inhibit key pro-inflammatory cytokines (TNF-α, IL-6) and NF-κB signaling, thereby countering peripheral sensitization. The TCM ointment contained Cortex Erythrinae (Hai Tong Pi) 30 g, Speranskia tuberculata (Tou Gu Cao) 30 g, Clematis chinensis (Wei Ling Xian) 30 g, Aconitum carmichaelii (prepared Chuanwu) 10 g, Aconitum kusnezoffii (prepared Caowu) 10 g, Zanthoxylum bungeanum (Hua Jiao) 10 g, Cyathula officinalis (Chuan Niu Xi) 30 g, Angelica sinensis (Dang Gui) 20 g, Luffae Fructus (Si Gua Luo) 10 g, Spatholobus suberectus (Ji Xue Teng) 20 g, Glycyrrhiza uralensis (Gan Cao) 6 g, and the penetration enhancer laurocapram (Azone) 5.4 g. Because Speranskia tuberculata was used here as one component of a complex multi-herb formula evaluated only in a rat model, no specific activity can be attributed to the individual herb from this study.
Evidence level: Preliminary in vitro / high-throughput screening only. No clinical evidence.
A large-scale laboratory screening study (Mazzio et al., 2014, published in Phytotherapy Research) evaluated 897 aqueous plant extracts for anti-mitotic effects against human breast carcinoma cells. Among the most potent anti-mitotics identified was Tou Gu Cao Speranskia herb (Speranskia tuberculata), ranking among a small number of highly active extracts out of nearly 900 screened.
The extract showed growth inhibition on BT-474 (human ductal breast carcinoma) and Ishikawa (human endometrial adenocarcinoma) cells, with ability to block replicative DNA synthesis, leading to G2 arrest in MDA-MB-231 cells.
In this large-scale laboratory screening of 897 aqueous plant extracts, Speranskia tuberculata was identified as one of the most potent anti-mitotic (cell-division-blocking) extracts against human breast cancer cells (MDA-MB-231). The extract inhibited cancer cell growth, blocked DNA replication, and caused cell cycle arrest. This is a preliminary finding from a screening study and does not constitute evidence for clinical anticancer use.
Separate cytotoxicity studies using MTT assays across multiple cancer cell lines have shown similar signals. The MTT cytotoxicity test was used to evaluate the effectiveness of extracts on five commercially available cell lines: A549 (human lung adenocarcinoma), HEPG2 (human hepatocellular carcinoma of the liver), A375 (human malignant melanoma), HELA (human pancreatic carcinoma), and RAW264.7 (macrophage-like cell line). In MTT tests, the viability during treatment of 4 out of 5 cell lines significantly decreased with increasing concentration of extracts. Only RAW264.7 cells were stable — their viability did not fall below 75–85%. Ethyl acetate extracts were the most effective, maximally reducing viability to 18%, with IC50 values for all cell lines varying between 49–53 μg/ml. For petroleum ether extracts, the IC50 of three lines was 65–74 μg/ml.
These findings are entirely in vitro and preliminary in nature. High-throughput screening results and cell-line cytotoxicity data are early-stage tools used to identify candidate compounds for further research; they do not demonstrate clinical efficacy or safety in humans.
Evidence level: Preliminary in vitro only. No clinical evidence.
Studies have assessed the antibacterial activity of different solvent extracts of Speranskia tuberculata against clinically relevant bacterial species. The aim was to determine the antibacterial activity of preparations of the herb, extracted with different solvents. Crude extracts were obtained using four solvents: petroleum ether, ethyl acetate, n-butanol, and aqueous solutions. Colonies of three types of bacteria — Staphylococcus aureus, Escherichia coli, and Propionibacterium acnes — were used as the object of the study.
According to the literature, twelve compounds found in the extracts have pronounced antibacterial activity. Of these, 8 of the 12 active antibacterial compounds belong to phenols and flavonoids, based on the presence of an aromatic ring and a carbon-linked hydroxyl group. These findings are entirely in vitro and no clinical trials in humans have been identified.
Based on both traditional use and the available scientific literature, Speranskia tuberculata is primarily associated with the following body systems and therapeutic areas:
Dosage information derives from traditional practice records and preclinical research. No standardized human clinical dosing from controlled trials has been established.
Some TCM sources classify Tou Gu Cao as having slight toxicity (有小毒), particularly the Impatiens balsamina form, while the Ben Cao Yuan Shi records the Speranskia form as non-toxic (无毒). In standard TCM classification, Herba Speranskiae Tuberculatae is labeled as pungent, bitter, warm, and slightly toxic, entering the liver and kidney meridians.
In animal safety testing of Speranskia tuberculata ethanol extract, no deaths were observed at oral doses up to 52.8 g/kg in mice (approximately 2,080 times the human clinical dose), suggesting a wide margin of safety. The study authors characterized STE as having a favorable safety profile. These findings are derived entirely from a rodent acute toxicity model and cannot be directly extrapolated to chronic human use or to populations with specific health conditions.
A critical safety consideration is the risk of misidentification. The persistent "same name, different plant" (同名异物) phenomenon represents one of the most significant quality control challenges for this herb in modern practice. Because at least 20 plant species from multiple botanical families are sold under the same Chinese name "Tou Gu Cao," consumers and practitioners sourcing this herb without verified botanical identity may be obtaining a different plant with a different safety and efficacy profile. This is particularly relevant because some substitute species may have their own distinct toxicological profiles.
No human clinical trials evaluating the safety of Speranskia tuberculata as a standalone intervention have been identified in the published peer-reviewed literature. The only human-relevant safety data available are the acute rodent toxicity studies described above. The herb's status as "slightly toxic" in several traditional classification systems warrants caution, and no data on drug-herb interactions, effects in pregnancy or lactation, or chronic-use toxicity have been documented in the accessible scientific literature.
The herb is commonly used in external wash preparations, which carry minimal systemic toxicity risk compared with oral ingestion.
The evidence base for Speranskia tuberculata is characterized by a large volume of traditional historical use but a very limited body of modern scientific investigation. Although Speranskia tuberculata has been widely applied to prevent and treat various diseases in Chinese folk medicine, few investigations are reported on its chemical composition and pharmacologic effects. The available peer-reviewed research consists entirely of:
No randomized controlled trials (RCTs), systematic reviews, pharmacokinetic studies in humans, or clinical dose-finding studies for Speranskia tuberculata as an isolated ingredient have been identified. All efficacy claims remain at the preclinical or traditional-use level. The anti-inflammatory and analgesic preclinical findings are internally consistent and provide a plausible mechanism to support the traditional applications, but the strength of clinical evidence is, at present, absent. The anti-cancer in vitro findings are preliminary and hypothesis-generating only.
Health conditions that Speranskia terburculata may help support.
Body systems that Speranskia terburculata may help support.
Go back